Remarkably, CBF-AML relapsed patients who received FLAG plus liposomal daunorubicin had a significantly better 4-year overall survival (82 vs. 58%) as compared to those who received FLAG alone (Kaspers et al., 2013). This evidence concerns the gene CEBPZ and acute myeloid leukemia.